RxDoctor Payments DataLook up a doctor →

Narendra Singh, MD

Cardiovascular Disease · Johns Creek, GANPI 1760477202

Payments from drug & device makers

$5,416,443in general payments, 2019–2025

Across 2,595 payments — averaging $2087.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$915K
  • Amgen$646K
  • Novo Nordisk AS$536K
  • Novartis$505K
  • Johnson & Johnson$486K
  • Novo Nordisk$326K
  • plus $2M from 46 others
$1,746in research payments, 2019–2025

Across 2 payments — averaging $872.77 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$2K

What the payments were for

  • Consulting fees$44,3013%
  • Speaking & faculty fees$1,362,03886%
  • Travel & lodging$142,9119%
  • Food & beverage$32,4062%
  • Education$3980%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,416,443 in reported general payments places this provider in the 95th percentile of 640 cardiovascular disease providers in Georgia.

See all cardiovascular disease providers in Georgia

Medicare billing

Part B allowed, 2024
$333,161
Medicare patients
361
Services billed
4,131

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban154$197,941
JardianceEmpagliflozin121$164,366
EntrestoSacubitril/Valsartan56$76,365
EliquisApixaban57$75,551
Repatha SureclickEvolocumab44$62,738
FarxigaDapagliflozin Propanediol46$48,182
KerendiaFinerenone25$43,827
Praluent PenAlirocumab15$13,036
VascepaIcosapent Ethyl15$7,893
Metoprolol Succinate323$3,619
Ranolazine ErRanolazine34$3,416
Atorvastatin Calcium437$3,312
Rosuvastatin Calcium226$2,587
Ezetimibe91$2,159
Midodrine Hcl24$1,612

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$485,940$197,941154 claims
Boehringer IngelheimJardiance$299,742$164,366121 claims
NovartisEntresto$505,350$76,36556 claims
PfizerEliquis$179$75,55157 claims
AstraZenecaFarxiga$212,171$48,18246 claims
BayerKerendia$204,742$43,82725 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 640 cardiovascular disease providers in Georgia.

Other cardiovascular disease in Johns Creek

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →